Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States.
Company profile
Ticker
ABT
Exchange
Website
CEO
Robert Ford
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Abbott Biologicals, LLC • Abbott Cardiovascular Inc. • Abbott Cardiovascular Systems Inc. • Abbott Delaware LLC • Abbott Diabetes Care Inc. • Abbott Diabetes Care Sales Corporation • Abbott Diagnostics Scarborough, Inc. • Abbott Equity Investments LLC • Abbott Finance LLC • Abbott Global LLC ...
IRS number
360698440
ABT stock data
Latest filings (excl ownership)
8-K
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
17 Apr 24
ARS
2023 FY
Annual report to shareholders
15 Mar 24
DEFA14A
Additional proxy soliciting materials
15 Mar 24
DEF 14A
Definitive proxy
15 Mar 24
10-K
2023 FY
Annual report
16 Feb 24
8-K
Entry into a Material Definitive Agreement
29 Jan 24
8-K
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
24 Jan 24
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
18 Oct 23
8-K/A
Submission of Matters to a Vote of Security Holders
1 Sep 23
Transcripts
ABT
Earnings call transcript
2024 Q1
17 Apr 24
ABT
Earnings call transcript
2023 Q4
24 Jan 24
ABT
Earnings call transcript
2023 Q3
18 Oct 23
ABT
Earnings call transcript
2023 Q2
20 Jul 23
ABT
Earnings call transcript
2023 Q1
19 Apr 23
ABT
Earnings call transcript
2022 Q4
25 Jan 23
ABT
Earnings call transcript
2022 Q3
19 Oct 22
ABT
Earnings call transcript
2022 Q2
20 Jul 22
ABT
Earnings call transcript
2022 Q1
20 Apr 22
ABT
Earnings call transcript
2021 Q4
26 Jan 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.71 bn | 6.71 bn | 6.71 bn | 6.71 bn | 6.71 bn | 6.71 bn |
Cash burn (monthly) | 375.33 mm | 240.42 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 2.59 bn | 1.66 bn | n/a | n/a | n/a | n/a |
Cash remaining | 4.11 bn | 5.05 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | 11.0 | 21.0 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
54.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2400 |
Opened positions | 257 |
Closed positions | 468 |
Increased positions | 804 |
Reduced positions | 1028 |
13F shares | Current |
---|---|
Total value | 99.47 tn |
Total shares | 951.96 mm |
Total puts | 3.12 mm |
Total calls | 2.45 mm |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 156.47 mm | $17.22 tn |
Capital Research Global Investors | 86.59 mm | $9.53 tn |
STT State Street | 74.69 mm | $8.22 tn |
Capital International Investors | 64.29 mm | $7.08 tn |
MS Morgan Stanley | 35.94 mm | $3.96 tn |
Wellington Management | 32.24 mm | $3.55 tn |
NTRS Northern Trust | 21.63 mm | $2.38 tn |
WFC Wells Fargo & Co. | 16.47 mm | $1.81 tn |
BK Bank Of New York Mellon | 15.12 mm | $1.66 tn |
LGEN Legal & General | 14.30 mm | $1.57 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 24 | John G Stratton | Stock Equivalent Units Common Shares | Grant | Acquire A | No | No | 113.66 | 323 | 36.71 k | 10,486 |
31 Mar 24 | Roman Michael F | Stock Equivalent Units Common Shares | Grant | Acquire A | No | No | 113.66 | 310 | 35.23 k | 3,650 |
31 Mar 24 | Patricia P. Gonzalez | Stock Equivalent Units Common Shares | Grant | Acquire A | No | No | 113.66 | 290 | 32.96 k | 3,174 |
31 Mar 24 | Alpern Robert J | Stock Equivalent Units Common Shares | Grant | Acquire A | No | No | 113.66 | 69 | 7.84 k | 9,628 |
29 Feb 24 | Robert B Ford | Common shares without par value | Payment of exercise | Dispose F | No | No | 120.05 | 31,610 | 3.79 mm | 220,059 |
News
Barclays Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140
22 Apr 24
Behind the Scenes of Abbott Laboratories's Latest Options Trends
18 Apr 24
Stocks Fall As Geopolitics, Economic Worries Spook Investors, Chipmakers Sell Off, Bitcoin Tumbles To $60,000: What's Driving Markets Wednesday?
17 Apr 24
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
17 Apr 24
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
17 Apr 24
Press releases
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
17 Apr 24
Abbott Hosts Conference Call for First-Quarter Earnings
27 Mar 24
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)
20 Mar 24
Medical Technology Stocks to Keep on The Radar (ORHB, MDT, BSX, ABT)
20 Feb 24
Medical Technology Stocks to Keep On The Radar
20 Feb 24